QOOLABS INC — Department of Health and Human Services SBIR Phase II: ODCDC

Description

HCV infects about of the world s population and most people are unaware of their infection status About of individuals with HCV infection develop chronic hepatitis and many progress to have cirrhosis and hepatocellular carcinoma HCC An early diagnosis in the course of the disease not only increases the chances of successful treatment but also effectively limits further transmission of HCV A rapid test that can be used for screening purposes will further improve the diagnosis rate and effectively prevent HCV infection transmission Unfortunately there are no rapid tests currently available for speedy diagnosis of HCV infection Qoolabs has developed a proprietary technology platform for isolating highly specific single domain antibodies and successfully applied these antibodies on lateral flow immunoassays LFIA In this study we propose to use this technology to develop HCV core antigen specific antibodies and to produce LFIA devices for rapid and early diagnosis of HCV